Comparative Study
[Risk-benefit analysis of intra-arterial and intravenous PGE1 infusions in peripheral arterial occlusive disorders]
[Article in
German]
Affiliations
- PMID: 1788752
Item in Clipboard
Comparative Study
[Risk-benefit analysis of intra-arterial and intravenous PGE1 infusions in peripheral arterial occlusive disorders]
[Article in
German]
Vasa Suppl.
1991.
Abstract
On the basis of pharmacological and clinical studies this review describes the effects of prostaglandin E1 (PGE1) on the cardiopulmonary system and its profile of adverse reactions taking into account spontaneous reports of side effects. All in all no increased risk of cardiovascular adverse reactions was obvious. PGE1 rather showed some desirable effects on heart and lung. Thus the analysis revealed a positive risk benefit relation for PGE1, provided that dosage and contra-indications are not neglected.
Similar articles
-
[Fibrinolytic activity, thrombocyte function and pharmacokinetics during intra-arterial or intravenous prostaglandin E1 infusion in patients with chronic arterial occlusive disease].Wien Klin Wochenschr. 1988 Jul 15;100(14):477-81. Wien Klin Wochenschr. 1988. PMID: 3062905 Clinical Trial. German.
-
[Prostaglandin E1 in therapy of peripheral arterial occlusive disease].Wien Klin Wochenschr. 1991;103(18):558-65. Wien Klin Wochenschr. 1991. PMID: 1750223 Review. German.
-
[Mechanisms of action of prostaglandin E1 in therapy of peripheral arterial occlusive diseases].Vasa. 2003 Nov;32(4):187-92. doi: 10.1024/0301-1526.32.4.187. Vasa. 2003. PMID: 14694766 Review. German.
-
Efficacy and tolerability of intra-arterial and intravenous prostaglandin E1 infusions in occlusive arterial disease stage III/IV.Vasa Suppl. 1989;28:31-8. Vasa Suppl. 1989. PMID: 2609242
-
[Effect of intra-arterial and intravenous PGE1 infusions on transcutaneous oxygen pressure in patients with critical ischemia of the extremities].Vasa Suppl. 1991;33:341-2. Vasa Suppl. 1991. PMID: 1788749 Clinical Trial. German.